Qian Wang Ph.D.

Inspired by nature’s ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function. Our team is designing novel therapies directed at regulatory hotspots, allowing us to treat diseases with limited or no known treatment options. Hotspot medicines are superior to conventional therapeutics given their exquisite selectivity, potent in vivo pharmacology and attractive drug-like properties.

Pivotal bioVenture Partners (U.S.), an affiliate of Pivotal Life Sciences We back the brightest minds in life sciences. Our seasoned investment team brings over 50 years combined biotech venture capital and company building experience from top tier funds including Novo Ventures, TPG Biotech, Bay City Capital, NEA, and SV Life Sciences. We strive to leverage this extended network and expertise in evaluating new investment opportunities, building value in our portfolio, and in contributing management talent and referrals to our companies. We invest at all stages in a company’s evolution, from company creation through mid and late stage clinical development. We are capable of leading or co-leading transactions, and employ a rigorous investment review process that distinguishes us and helps us with syndicate building and positioning companies well for a future public offering or M&A event.

Inspired by nature’s ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function. Our team is designing novel therapies directed at regulatory hotspots, allowing us to treat diseases with limited or no known treatment options. Hotspot medicines are superior to conventional therapeutics given their exquisite selectivity, potent in vivo pharmacology and attractive drug-like properties.

Pivotal bioVenture Partners (U.S.), an affiliate of Pivotal Life Sciences We back the brightest minds in life sciences. Our seasoned investment team brings over 50 years combined biotech venture capital and company building experience from top tier funds including Novo Ventures, TPG Biotech, Bay City Capital, NEA, and SV Life Sciences. We strive to leverage this extended network and expertise in evaluating new investment opportunities, building value in our portfolio, and in contributing management talent and referrals to our companies. We invest at all stages in a company’s evolution, from company creation through mid and late stage clinical development. We are capable of leading or co-leading transactions, and employ a rigorous investment review process that distinguishes us and helps us with syndicate building and positioning companies well for a future public offering or M&A event.

BlackRock is a global asset manager and technology provider dedicated to helping more and more people experience financial well-being. We help millions of people invest to build savings that serve them throughout their lives. We always start with our clients’ needs and look to offer them more quality choices for how and where to invest their money. Our global investments platform offers our clients access to the world’s markets while making investing easier and more affordable. And with offices in more than 40 countries, our global expertise helps them navigate changing markets to stay ahead of the curve. Follow us for global insights shaping the economy, conversations about financial well-being and more information on culture and careers at BlackRock. https://bit.ly/3n6Fxdy

From local communities to global markets, we are dedicated to shaping the future responsibly and helping clients thrive in a changing world. “Bank of America Merrill Lynch” is the marketing name for the global banking and global markets businesses of Bank of America Corporation. Bank of America is a marketing name for the Retirement Services business of Bank of America Corporation. Lending, derivatives, and other commercial banking activities are performed globally by banking affiliates of Bank of America Corporation, including Bank of America, N.A., Member FDIC. Securities, strategic advisory, and other investment banking activities are performed globally by investment banking affiliates of Bank of America Corporation (“Investment Banking Affiliates”), including, in the United States, BofA Securities, Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, and Merrill Lynch Professional Clearing Corp., all of which are registered broker-dealers and Members of SIPC, and in other jurisdictions, by locally registered entities. BofA Securities, Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated and Merrill Lynch Professional Clearing Corp. are registered as futures commission merchants with the CFTC and are members of the NFA.   Investment products: Are Not FDIC Insured May Lose Value Are Not Bank Guaranteed Any opinions, views, statements, estimates or projections (“posts”) posted on this web page are solely those of the individual author(s). As such, posts by an employee of BofAML or any of its affiliates are solely those of such employee or agent and do not necessarily reflect the views of BofAML. BofAML is not responsible for the content, or output of external websites. For Terms and Conditions and Disclaimers, please visit go.bofaml.com/social. Bank of America LinkedIn Community Guidelines can be found at: http://about.bankofamerica.com/en-us/social-media/linkedin-community-guidelines.html

Deallus is a global life science consultancy with a heritage in Competitive Intelligence. Our vision is to lead the industry in shaping and refining strategies for those striving to advance healthcare and improve patients’ lives. For two decades Deallus has been the partner of choice for pharma, biotech, and med-tech to help our clients achieve this. Today we work alongside the world’s global leading pharma companies, as well as emerging biopharma, partnering with our clients across multiple projects and over many years. We are a team of commercial scientists which allows for a peer-to-peer partnerships with our clients through a shared understanding of how science intersects with commercial market realities. For our clients we become an extension of their internal teams, enabling us to generate bespoke solutions to organisational needs and ambitions. Operating in key pharma markets, we retain and develop top talent, nurturing our team by cultivating a diverse and inclusive culture. Clients value our expertise in market dynamics and depth of therapeutic areas to deliver the actionable insights that drive innovation. We’re proud of the part we’ve played in helping clients prepare for the future, achieve competitive advantage and allowing their organisations to remain at the forefront of the industry. Our therapy area expertise, including neuroscience, oncology, rare diseases, and vaccines, and our global reach serve clients areas including: business insights, market access, value and pricing, R&D, portfolio strategy, medical affairs, and brand and marketing. Our outputs are tailored to the client challenge and leveraging a range of methodologies including primary research, market landscaping, workshops, and forecasting.